Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3020 in Solid Tumors
NCT06963281Phase 1Recruiting
- Sponsor
- Fortvita Biologics
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of IBI3020 in solid tumor, sponsored by Fortvita Biologics. Primary endpoints: Adverse Events up to 3 years, Clinically Significant Changes in Physical Examination Results up to 3 years and 5 more. Started Apr 2025; status: recruiting.
02
Drugs
IBI3020
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06963281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963281.